Summer Skin Essentials
Time to switch up your skin care regimen for summer
MISSION, Kan., June 16, 2025 /PRNewswire/ -- (Family Features) Summer is all about sunshine, vacations and outdoor adventures, but warmer weather and environmental changes can be harsh on your skin. Excessive sun exposure, sweating and dehydration can leave your skin feeling less than its best. Thankfully, with the right skin care essentials, you can maintain glowing, hydrated skin all season long.
Explore top solutions for summer skin care, chosen from Herbacin's Skin Solutions and Foot Care lines, and discover how they can restore and protect your skin from summer stressors no matter the adventure at herbacinusa.com.
Deep Cleansing for Radiant SkinSummer heat makes oily, sweaty skin more common, leading to clogged pores and dullness. That's why a gentle yet powerful exfoliation is crucial with a solution like Gentle Face Scrub, which is formulated with exfoliating jojoba wax particles to remove dead skin cells and cleanse deep into the pores. Infused with aloe vera, chamomile and marigold, this scrub eliminates impurities while promoting skin regeneration. Plus, it's suitable for all skin types and is free from parabens and mineral oils.
How to Use: Apply the scrub 1-2 times per week for instantly smoother, brighter skin.
Hydration That Lasts All DayHydration is key to maintaining healthy, youthful skin. Try Daily Skin Moisturizer that offers 24-hour hydration thanks to its hyaluronic acid-rich formula. Enhanced with inositol for elasticity and fucose biopolymer for moisture retention, it deeply nourishes your skin without leaving an oily residue. It's gentle enough for sensitive skin and perfect relief for sun exposure or after a day outdoors.
Pro Tip: Apply this lightweight moisturizer as the final step in your morning skin care routine for all-day skin hydration.
Soothe and Clear Blemishes QuicklyConsider Anti-Blemish Gel to keep your skin clear and blemish free. Packed with soothing aloe vera, chamomile, marigold, panthenol and bisabolol, this targeted treatment promotes skin healing while drying out blemishes and reducing irritation. Its anti-inflammatory properties make it ideal for tackling acne and preventing future breakouts.
How to Use: Apply a small amount to blemishes several times a day until the irritation subsides.
Nourishment for Stressed and Rough AreasSun, saltwater and chlorine can cause specific areas of the body, like elbows and hands, to become rough and dehydrated. Designed to restore softness, this Special Care Cream improves skin elasticity in even the driest areas. Enriched with plant-based glycerin, allantoin and vitamin E, this cream provides intensive nourishment and protection without a greasy finish.
Essential Tip: Apply regularly to areas prone to dryness for soft, smooth skin all summer.
Extra TLC for Your FeetBetween barefoot walks on the beach and sandal season, your feet deserve special attention. Take care of them with Herbacin's Foot Care line, which includes a range of products such as Leg Lotion, Cooling Gel and Foot Cream, designed to revitalize tired legs and feet. Infused with active ingredients like red vine leaves and horse chestnut, these products boost circulation, tone the skin and prevent the formation of calluses and cracks.
Step Up Your Routine:
Smooth on the Leg Lotion to nourish and protect legs and feet from dehydration.
Use the Cooling Gel after a long day to soothe sore legs.
Apply Foot Cream overnight to soften and maintain smooth, crack-free skin.
Michael Frenchmfrench@familyfeatures.com 1-888-824-3337editors.familyfeatures.com
About Family Features Editorial SyndicateA leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at Culinary.net and eLivingToday.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/summer-skin-essentials-302482589.html
SOURCE Family Features Editorial Syndicate
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Chronic Hepatitis B Market--The US to Have the Lion's Share Among the 7MM, Predicts DelveInsight
The chronic hepatitis B market size is predicted to surge owing to the increasing prevalence of the disease globally and rising awareness about early diagnosis and treatment. Advances in antiviral therapies and the development of novel treatment options are fueling market expansion. LAS VEGAS, June 17, 2025 /PRNewswire/ -- Hepatitis B is the most widespread serious liver infection globally, caused by the hepatitis B virus (HBV), which targets and damages the liver. Millions of individuals worldwide are affected by chronic hepatitis B. The virus spreads through contact with infected blood and bodily fluids, including transmission via unprotected sex, sharing of contaminated needles, use of illegal drugs, and exposure to unsterilized medical equipment. In most cases, hepatitis B resolves on its own within 1 to 2 months. However, if the infection persists beyond six months, it can become chronic, potentially leading to ongoing liver inflammation, cirrhosis (liver scarring), liver cancer, or liver failure. As of 2024, around 5 million people across the 7MM were living with chronic hepatitis B. Among these, 85% had compensated liver function, while the remaining 15% had progressed to decompensated liver disease. Currently, there is no definitive cure for hepatitis B. Antiviral medications and interferon injections can help manage the disease by reducing viral activity and easing symptoms, but they do not eliminate the virus entirely. If the infection persists beyond six months, it is classified as chronic, making patients eligible for drug therapy, particularly those with active liver disease. Learn more about the chronic hepatitis B virus market @ New Treatment for Chronic Hepatitis B The US FDA has approved seven medications for treatment: two injectable interferons and five oral antiviral drugs. These treatments must be taken daily and work by suppressing viral replication, thereby reducing liver inflammation and potential damage. VEMLIDY (tenofovir alafenamide), developed by Gilead Sciences, is an innovative, targeted prodrug of tenofovir formulated as an oral tablet. In March 2024, Gilead announced that the FDA had approved a supplemental New Drug Application (sNDA) for VEMLIDY 25 mg, allowing its once-daily use in pediatric patients aged 6 years and older and weighing at least 25 kg who have chronic hepatitis B (CHB) infection with compensated liver disease. Earlier, in November 2022, the FDA approved the same 25 mg dose for once-daily use in children aged 12 and above with CHB and compensated liver disease. The initial FDA approval came in November 2016 for adult patients with CHB and compensated liver function. In January 2017, Gilead announced that the European Commission (EC) had granted marketing authorization for VEMLIDY 25 mg to treat CHB in adults and adolescents aged 12 and older who weigh at least 35 kg. Additionally, in December 2016, Japan's Ministry of Health, Labour and Welfare (MHLW) approved VEMLIDY for the treatment of chronic hepatitis B in patients showing active viral replication and abnormal liver function. Find out more on FDA-approved chronic hepatitis B drugs @ Chronic Hepatitis B (CHB) Market The chronic hepatitis B treatment drug market is continuously evolving. Several pharma companies are evaluating their lead assets in different phases of development. Many potential therapies are being investigated to manage chronic hepatitis B. Some of the drugs in the pipeline include Imdusiran (AB-729) (Arbutus Biopharma), GSK3228836 (bepirovirsen) (GlaxoSmithKline), Tobevibart (VIR-3434) + elebsiran (VIR-2218) ± PEG-IFN-a (Vir Biotechnology), and others. Even though it is too soon to comment on the above-mentioned promising candidate to enter the market during the forecast period (2025–2034), it is safe to assume that the future of this market is bright. Discover which therapies are expected to grab major chronic hepatitis B treatment drug market @ Chronic Hepatitis B Market Report Daplusiran (also known as tomligisiran, formerly JNJ-3989/GSK5637608) is an experimental siRNA-based therapy targeting hepatitis B virus (HBV). It is being studied in combination with bepirovirsen in a sequential regimen for adult patients with chronic hepatitis B who are non-cirrhotic and receiving nucleos(t)ide analogue (NA) therapy. In October 2023, GSK and Arrowhead Pharmaceuticals announced an agreement with Janssen Pharmaceuticals to acquire the exclusive global rights to further develop and commercialize JNJ-3989. Janssen had originally licensed the drug (then called ARO-HBV) from Arrowhead in 2018. Imdusiran is an RNA interference (RNAi) therapy designed to suppress all HBV viral proteins and antigens, including HBsAg, which is believed to be critical for restoring the immune system's ability to fight the virus. It uses Arbutus' proprietary GalNAc-conjugated delivery platform to specifically target liver cells (hepatocytes), allowing for subcutaneous administration. Arbutus plans to launch a Phase IIb clinical trial in the first half of 2025 to evaluate imdusiran in combination with interferon (IFN) and NA therapy. Discover more about drugs for chronic hepatitis B in development @ Chronic Hepatitis B Clinical Trials The anticipated launch of these emerging therapies for chronic hepatitis B are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic hepatitis B market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for chronic hepatitis B is expected to grow at a significant CAGR by 2034. In 2024, the United States dominated the CHB market among the 7MM, capturing approximately 72% of the total market share. The market size of chronic hepatitis B is expected to grow due to several factors, including rising global prevalence of hepatitis B virus infection and increasing awareness about the disease. Advances in antiviral therapies and growing screening initiatives also boost market growth by enabling early diagnosis and improved disease management. DelveInsight's latest published market report, titled as Chronic Hepatitis B Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the chronic hepatitis B country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The chronic hepatitis B market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Chronic Hepatitis B Total Diagnosed Cases of Chronic Hepatitis B Chronic Hepatitis B Cases by Age Group Chronic Hepatitis B Cases by Gender Treated Cases of Chronic Hepatitis B Chronic Hepatitis B Cases by Impact on Liver The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM chronic hepatitis B market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this chronic hepatitis B market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the chronic hepatitis B market. Also, stay abreast of the mitigating factors to improve your market position in the chronic hepatitis B therapeutic space. Related Reports Chronic Hepatitis B Epidemiology Chronic Hepatitis B Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the CHB epidemiology trends. Chronic Hepatitis B Pipeline Chronic Hepatitis B Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CHB companies, including Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, among others. Hepatitis A Market Hepatitis A Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatitis A companies, including Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, among others. Hepatitis C Market Hepatitis C Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatitis C companies, including AbbVie, Gilead Sciences, Atea Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
8 hours ago
- Yahoo
Infectious Disease Testing Surges to $29B: Kalorama Report Highlights Molecular Breakthroughs and Point-of-Care Growth in IVD Market
ARLINGTON, Va., June 17, 2025 /PRNewswire/ -- Kalorama Information, a leading authority in healthcare market intelligence, has released the latest edition of its bimonthly publication, In Vitro Diagnostics Business Outlook. Now in its fourth year, the most recent issue is a comprehensive market briefing offering exclusive insights into the evolving landscape of infectious disease testing—one of the most dynamic sectors within the global in vitro diagnostics (IVD) market. Previous issues have covered key IVD topics including cardiac biomarkers, glucose testing, point-of-care testing, blood screening, clinical chemistry, molecular HLA testing, and more. According to the latest issue, the infectious disease testing market reached an estimated $29 billion in 2024, with COVID-19 testing accounting for 18% of total revenue, even as demand declines post-pandemic. Non-COVID point-of-care (POC) testing continued its upward trajectory, increasing by mid-single digits, and the segment remains a critical driver of diagnostic innovation globally. "The infectious disease testing market is highly concentrated in North American and European markets, with a combined share exceeding three-quarters of the global market," said Daniel Granderson, Senior Editor at Kalorama Information. "However, distribution is slowly shifting as emerging markets ramp up adoption of molecular platforms and POC innovations." The report highlights the growing impact of next-generation technologies, including alternative PCR methods, microarrays, NGS, and mass spectrometry. Instrument-automated analysis and miniaturized platforms are enabling broader deployment across physician offices, mobile health clinics, and even home settings—marking a transformational shift in test accessibility. Other key insights from this edition: Molecular diagnostics remain concentrated in developed countries but show new growth in Latin America, Southeast Asia, and Africa. Point-of-care testing is increasingly pivoting to non-COVID applications, such as respiratory panels, STIs, and antimicrobial resistance surveillance. Investment, M&A, and R&D activity remain robust across diagnostic segments, as companies reorient toward long-term growth drivers beyond pandemic response. A Strategic Resource for Healthcare Decision-Makers In Vitro Diagnostics Business Outlook delivers six issues annually, each exploring a high-value IVD market segment. It is designed for: Corporate strategy teams seeking growth forecasts and pipeline planning data R&D and innovation leads tracking platform adoption and market shifts Investors and financial analysts evaluating diagnostic business models and M&A targets Clinical lab leaders and health policy experts seeking diagnostic utilization trends and access insights Each issue includes: Market forecasts, growth rates, and share analysis Company and product profiles M&A and partnership tracking Geographic and regulatory trends Expert commentary and exclusive news analysis Order Now The full report can be purchased at: For purchase or custom consultation, contact:Sheri Davie, Sales About Kalorama Information Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website. View original content to download multimedia: SOURCE Kalorama Information Sign in to access your portfolio
Yahoo
9 hours ago
- Yahoo
1nHealth Honors 25 Patient Engagement Leaders Making a Difference in Clinical Research
ORLANDO, Fla., June 17, 2025 /PRNewswire/ -- 1nHealth, a leader in clinical trial patient recruitment and enrollment, announced the winners of its inaugural Patient Engagement Leaders Award. These 25 leaders are redefining what it means to serve patients—not just as participants, but as partners in research. Spanning biotech, pharma, CROs, advocacy, and site organizations, the 25 Patient Engagement Leaders Award winners were selected from over 100 nominations representing more than 50 companies across the life sciences industry. Chosen for their real-world contributions to making clinical trials more accessible, inclusive, and patient-centric, these leaders are elevating patient voices throughout the trial process and creating new models for trust and transparency—setting a new standard for what it means to truly engage patients in research. "1nHealth's first annual Patient Engagement Awards shines a much-needed spotlight on the unsung heroes in clinical research making trials more human, accessible, and patient-centered," said Dan Brenner, Founder & CEO of 1nHealth. "It's an honor to celebrate these winners—individuals who embody the very values that define 1nHealth and those driving meaningful impact across the industry: authenticity, dedication, and curiosity." Patient engagement isn't just a step in the clinical trial process. It's the key to safer and more effective therapies, and it doesn't happen by accident. It happens because of dedicated professionals who go above and beyond to ensure patients are heard, valued, and empowered. Browse the full list of honorees and their stories here. The annual Patient Engagement Leaders Award list will continue to grow, with nominations for 2026 opening early next year. About 1nHealthFrom kick-off to last patient in, 1nHealth builds a reliable source of referred enrollments through proven recruitment programs and high-touch patient engagement. With over 30,000 patients enrolled across more than 150 studies, 1nHealth helps study sponsors and clinical research organizations overcome enrollment challenges, connect diverse patient populations to clinical studies, and improve trial outcomes. Contact Information:1nHealthRyan View original content to download multimedia: SOURCE 1nHealth Sign in to access your portfolio
